Latest news with #ICONplc
Business Wire
3 days ago
- Business
- Business Wire
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledging ICON's leadership in the application of innovative AI technologies in the industry, the organisation won the AI Project of the Year Award at the Analytics & AI Awards. The award honoured ICON's secure, enterprise-grade AI Assistant that streamlines work across functions, enabling faster insights, automating tasks, and scaling decision support through large language models (LLMs), with several agents live and thousands of global users onboarded. ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards. This recognition is based on feedback shared by ICON employees in India and reflects the inclusive culture the company strives to foster through its ongoing commitment to creating a workplace where women can thrive, lead, and grow. In Asia Pacific, the company was awarded Best CRO in APAC at the 2025 Asia Pacific Biopharma Excellence Awards. The awards honour outstanding achievements in Asian bioprocessing, logistics, supply chain management, and clinical trials, celebrating current industry leaders while inspiring future innovators. ICON's award recognises the organisation and its employees' outstanding efforts and positive contribution in the APAC region. At the PharmaTimes International Clinical Researcher of the Year awards, recognising the talent and passion of clinical researchers from across the globe, ICON boasted over 30 employees who received gold, silver, and bronze awards or who were nominated as finalists. In recognition of the progress the company has made in sustainability, ICON was included on two TIME Magazine rankings: 'World's Best Companies in Sustainable Growth 2025' and 'World's Most Sustainable Companies 2025'. In the former list, which compiles companies who demonstrate both outstanding financial and environmental performance, ICON featured at number 57 out of 500 companies, and was listed as the highest CRO globally and the second highest Irish-based organisation. In the latter list, which ranks the world's 500 most sustainable companies based on their public commitment to, and progress toward, sustainability targets, ICON was included as one of only four CROs, and one of nine Irish companies. Steve Cutler, CEO, ICON commented: 'These achievements once again recognise the dedication of our employees, who go above and beyond every day to deliver the best value to our customers. This is further reflected in the recognition our teams have received in the AI and sustainability space, and well-earned acknowledgement for how we are driving innovation for the future of clinical research and the planet.' A full list of ICON's industry awards can be viewed at About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: ICON/ICLR-G
Business Wire
23-06-2025
- Business
- Business Wire
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
Any changes to this event and links to the live webcast will be posted on the Investor section of our website under ' Events '. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at
Associated Press
23-06-2025
- Business
- Associated Press
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--Jun 23, 2025-- ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under ' Events '. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: . This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word 'expected' and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at . ICON/ICLR-G View source version on Kate Haven Vice President Investor Relations +1888 381 7923 KEYWORD: IRELAND EUROPE INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH MEDICAL DEVICES HEALTH TECHNOLOGY SOURCE: ICON plc Copyright Business Wire 2025. PUB: 06/23/2025 06:30 AM/DISC: 06/23/2025 06:29 AM
Business Wire
27-05-2025
- Business
- Business Wire
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT. Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under ' Events '. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at
Yahoo
19-05-2025
- Business
- Yahoo
ICON releases its ICON Cares 2024 Report
DUBLIN, May 19, 2025--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program. In recognition of its efforts in 2024, ICON received a score of 72/100 from EcoVadis, a leading provider of business sustainability ratings, an increase of two points on the previous score, earning ICON a silver medal. ICON also achieved a B- score on its CDP Climate Change response. Most recently, ICON has been named by TIME magazine as one the World's Best Companies in Sustainable Growth 2025 and the highest ranked CRO. On the publication of the report, ICON's CEO, Dr. Steve Cutler commented: "Our industry continues to rapidly evolve – sitting at the confluence of the AI revolution and a parallel revolution in biomedical science. This represents an unprecedented opportunity to address unmet clinical need and to impact the lives of countless patients. As we embrace these changes, we remain focused on delivering on our ICON Cares commitments to our patients, customers, people and planet." The ICON Cares 2024 Report is available here. Highlights in the report include: Continued focus on improving public health and increasing access to clinical trials ICON recognises access to healthcare as a fundamental human right. In 2024, we continued strides towards improving patients' lives and concentrated on expanding trial access and improving representation for all participants, trial investigators and community and patient advocacy groups. In 2024, ICON supported over 1,270 clinical studies involving over 416,000 patients. Our efforts contributed to 19 medicines receiving original or supplemental approval. Innovation and artificial intelligence (AI) ICON, powered by healthcare intelligence, is devising innovative solutions, leveraging technology, data and partnerships to enhance patient access to clinical trials and to reduce the time from clinical trial to drug approval. ICON expanded its capabilities in AI and robotic process automation in 2024, enhancing efficiency, execution and delivery for its customers. Governance around this evolving technology was also strengthened while ensuring that our automated solutions always factor in human oversight and comply with regulations. Minimising environmental footprint in our operations In October 2024, ICON's near-term, long-term and net-zero science-based targets were validated by the Science Based Targets initiative (SBTi). We have exceeded our near-term SBTi target of 61.2% by 2028 as we have achieved a 70.06% reduction in Scope 1 & 2 Green House Gas (GHG) emissions. We continue to work towards achieving our Scope 3 emissions reduction and long-term targets. Also, we have reduced kit wastage by 15-20% in our laboratories business on certain studies by analysing historical sponsor data and site behaviours using active kit management. ICON also continued to make improvements against our other environmental targets in 2024 including: 84.67% of electricity consumed in 2024 came from renewable sources 18.8% reduction in kilowatt hours of electricity compared to 2018 For further information about ICON Cares, please visit This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: ICON/ICLR-G View source version on Contacts Media contacts: Lisa Henry, Weber Shandwick (PR adviser)+44 7785 458203lhenry@ Kate Haven, Vice President Investor Relations, ICON+1-888-381-7923IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
